ArticleScientific reports2025
Exploration of shared pathogenic factors and causative genes in early-stage endometrial cancer and osteoarthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA FOXP4-AS1 promotes glioma cell proliferation, metastasis, and glycolysis via the miR-136-5p/ADCYAP1R1 axis.Functional & integrative genomics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Osteoarthritis (OA) has been implicated in the development and progression of early-stage endometrial cancer (EC), suggesting shared pathogenic factors between the two diseases. This study aimed to investigate the causal relationship between OA and EC and to identify causative genes common to both early-stage EC and OA. A Two-sample Mendelian randomization (MR) analysis was first performed to assess the causal relationship between OA and EC. Differentially expressed genes associated with early-stage EC and OA were identified using the limma package. Overlapping genes were extracted to determine common causative genes, followed by enrichment analysis. The causal relationship between these genes and EC was verified through Mendelian randomization (MR) of drug targets. Genes with diagnostic value were identified using multiple machine learning algorithms to construct EC prediction models and evaluate their performance. Additionally, the study examined the correlation between diagnostic-value genes and immune cell infiltration. IVW analysis indicated that OA was a high-risk factor for the development of EC (P < 0.05). Seven common causative genes (CDKN2A, DDA1, LRRC42, POLB, ADCYAP1R1, DNMT3A, and GLRX5) were identified for OA and EC, showing significant enrichment in related pathways such as heterochromatin. MR analysis of drug targets revealed that CDKN2A, DDA1, LRRC42, and POLB had diagnostic value for EC. The EC prediction model based on these four genes demonstrated high performance (AUC = 0.974 for the training set; AUC = 0.966 for the validation set), and these genes were significantly associated with immune cell infiltration (P < 0.05). CDKN2A, DDA1, LRRC42, and POLB may be common causative genes for OA and early-stage EC, potentially serving as targets for drug intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.